Valneva Installs Vaccine Veteran as Chair, Signaling Pipeline Focus

LYON, FRANCE – June 25, 2026 – For many companies, the Annual General Meeting is a procedural affair, a formal check-box on the corporate calendar. But for Valneva SE, a specialty vaccine company at a critical juncture, today's AGM in Lyon was a statement of intent. Shareholders unanimously approved a slate of resolutions that not only shored up the company's governance and financial footing but, most significantly, installed a heavyweight of the vaccine world, Dr. Gerd Zettlmeissl, as the new Chair of its Board of Directors.

This move, coupled with strategic operational shifts and renewed financial authorizations, isn't just a leadership shuffle. It’s a clear signal that Valneva is meticulously aligning every facet of its organization—from the boardroom to its balance sheet—to execute on its high-stakes pipeline, most notably its partnered Lyme disease candidate and the world's most advanced Shigella vaccine candidate. For a company defined by its focused pursuit of first-in-class vaccines, the appointment of a seasoned veteran at the helm speaks volumes.

A Veteran Returns to the Helm

The headline appointment of Dr. Gerd Zettlmeissl is more than a formality; it's a strategic masterstroke. With over 40 years in the biopharmaceutical industry, Dr. Zettlmeissl is not just an experienced director but a foundational figure in Valneva's own history. He previously served as CEO of Intercell AG from 2001 to 2011, the very company that merged to become Valneva. During his tenure, he transformed Intercell from a private startup into a public company, overseeing the successful launch of a Japanese Encephalitis vaccine and building a broad development portfolio.

His expertise is precisely what a company like Valneva needs as it navigates the final, most challenging stages of clinical development and prepares for potential commercialization. His track record extends beyond Intercell, including senior roles at Chiron Corp and Behringwerke AG, and successful chairmanships at companies like GlycoVaxyn (acquired by GSK) and Themis Bioscience (acquired by Merck). This history of guiding biotech firms toward major value inflection points—be it regulatory approval or strategic acquisition—is an invaluable asset. He is, in essence, a specialist in turning scientific promise into market reality.

In his new role, Dr. Zettlmeissl succeeds Anne-Marie Graffin, who skillfully chaired the board for the past three years and will now provide continuity as Vice-chair. This ensures a smooth transition, blending new leadership with deep institutional knowledge. Dr. Zettlmeissl commented on his appointment, stating, “I am honored to be appointed chair of the Board and would like to thank Anne-Marie for her outstanding leadership during her tenure. I look forward to working closely with my fellow board colleagues and the management team to support Valneva’s strategic priorities and long-term value creation for shareholders.” His return to a leadership position is a powerful endorsement of the company's direction and a clear indicator to investors that the board is being steered by a hand intimately familiar with the complexities of vaccine development.

Fortifying Governance and Streamlining Operations

Beyond the leadership change, the AGM solidified Valneva's corporate structure to support its ambitions. Shareholders approved the reappointment of five board members, including CEO Thomas Lingelbach, for staggered terms ranging from one to three years. This practice is a hallmark of stable corporate governance, ensuring continuity by preventing a complete board turnover in a single year. It provides a bedrock of experience and strategic memory, which is crucial during the multi-year cycles of vaccine development.

The meeting also formally approved the transfer of the company's registered office to Lyon, following the closure of its site in Nantes. On the surface, this is an administrative move, but it represents a deliberate consolidation of operations. By centralizing its French headquarters in Lyon, a major European biotech hub, Valneva can streamline administrative functions, improve operational efficiency, and tap into a rich ecosystem of talent and resources. This physical consolidation mirrors the company's focused strategic approach, eliminating redundancies to better direct resources toward its primary mission: advancing its pipeline.

These governance and operational decisions, all unanimously approved, demonstrate a strong alignment between the board, management, and shareholders. It reflects confidence in the current strategy and a collective commitment to creating a lean, stable, and effective organization capable of navigating the regulatory and commercial hurdles that lie ahead.

The Financial Fuel for Breakthroughs

A sharpened strategy and expert leadership are only effective if backed by a strong financial foundation. The AGM addressed this by approving the 2025 financial statements and, critically, renewing authorizations for the Board of Directors regarding the company’s share capital. This isn't merely procedural; it is the mechanism that gives Valneva the agility to fund its future.

These authorizations empower the board to raise capital efficiently, whether to fund the final phases of its Lyme disease vaccine trials with Pfizer, accelerate the development of its Shigella candidate, or invest in its manufacturing capabilities. For a biotech company without the massive revenue streams of a pharmaceutical giant, this financial flexibility is paramount. It allows management to seize opportunities and navigate the capital-intensive R&D process without being hamstrung by lengthy shareholder approval processes for every financial decision.

This vote of confidence comes on the back of a strong period for the company, which reported a solid cash position at the end of the last quarter and has seen significant investor interest, reflected in its share price performance over the past year. By securing its financial and operational base at the AGM, Valneva has ensured it has the leadership, structure, and resources in place to continue its progress. The pieces are being moved with precision, all pointing toward the company's goal of delivering on the promise held within its specialized and much-needed vaccine pipeline.